Mepolizumab Market Report 2026

Mepolizumab Market Overview

• Mepolizumab market size has reached to $2.22 billion in 2025 • Expected to grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: The Increasing Global Burden Of Asthma Is Driving The Market Due To Rising Prevalence And Demand For Targeted Biologic Therapies • Market Trend: Expansion Of Biologic Therapies Into Broader Chronic Respiratory Disease Indications • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mepolizumab Market?

Mepolizumab is a humanized monoclonal antibody that selectively targets and inhibits interleukin-5, a cytokine responsible for the growth, activation, and survival of eosinophils, thereby reducing eosinophilic inflammation and modulating immune system activity in disorders characterized by elevated eosinophil levels. It is primarily used in the management of severe eosinophilic asthma and other eosinophil-associated conditions, where it helps decrease exacerbation frequency, improve symptom control, and reduce the need for systemic corticosteroid therapy. The main indications of mepolizumab include severe asthma, eosinophilic granulomatosis with polyangiitis, chronic obstructive pulmonary disease, and other eosinophilic disorders. Severe asthma refers to a form of asthma characterized by persistent symptoms and frequent exacerbations despite high-intensity treatment. These indications are used across age groups including children 6 to 11 years, adolescents 12 to 17 years, and adults 18 years and older. They are distributed through direct sales, retail pharmacy, and online pharmacy channels, while endusers involved are hospitals, clinics, and home care settings.

What Is The Mepolizumab Market Growth Forecast?

The mepolizumab market size is expected to see strong growth in the next few years.It will grow to $3.21 billion by 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, expansion of biologics pipeline, growing demand for home-based treatment options, advancements in targeted immunotherapies, rising healthcare investments in chronic disease management.Major trends in the forecast period include increasing adoption of monoclonal antibody therapies, growing use of biologics for severe asthma management, rising demand for steroid-sparing treatment options, expanding clinical applications in eosinophilic disorders, improved patient adherence through targeted therapies.

Global Mepolizumab Market Segmentation

1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis, Chronic Obstructive Pulmonary Disease, Other Eosinophilic Disorders 2) By Age Group: Children 6 To 11 Years, Adolescents 12 To 17 Years, Adults 18 Years And Older 3) By Distribution Channel: Direct Sales, Retail Pharmacy, Online Pharmacy 4) By End User: Hospitals, Clinics, Home Care Settings Subsegments: 1) By Severe Asthma: Allergic Severe Asthma, Non Allergic Severe Asthma, Late Onset Severe Asthma 2) By Eosinophilic Granulomatosis With Polyangiitis: Active Eosinophilic Granulomatosis With Polyangiitis, Relapsing Eosinophilic Granulomatosis With Polyangiitis, Remission Phase Eosinophilic Granulomatosis With Polyangiitis 3) By Chronic Obstructive Pulmonary Disease: Chronic Bronchitis Dominant Chronic Obstructive Pulmonary Disease, Emphysema Dominant Chronic Obstructive Pulmonary Disease, Frequent Exacerbator Chronic Obstructive Pulmonary Disease 4) By Other Eosinophilic Disorders: Hypereosinophilic Syndrome, Eosinophilic Esophagitis, Eosinophilic Chronic Rhinosinusitis

What Are The Drivers Of The Mepolizumab Market?

The increasing global burden of asthma is expected to propel the growth of the mepolizumab industry going forward.Asthma refers to a chronic respiratory condition in which the airways (bronchi) become inflamed, narrow, and produce excess mucus, making it difficult to breathe.The rise of asthma is due to people being exposed to a combination of genetic and environmental factors, which can trigger inflammation in the airways of the body and make the lungs more sensitive, which leads to a higher prevalence of asthma.Mepolizumab helps asthma by allowing the reduction of inflammation caused by eosinophils, which are a type of white blood cell that contributes to airway swelling and asthma attacks.For instance, in February 2026, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based independent statutory agency, asthma contributes 2.5% to Australia’s total disease burden in 2024, is the leading cause of disease burden among children aged 1-9, drives approximately $1.3 billion in healthcare spending in 2023-24, and shows higher prevalence and hospitalization rates in boys compared to girls.Furthermore, in February 2023, according to NHS England, a UK-based executive non-departmental public body, approximately 5.4 million individuals are undergoing asthma treatment, with around 160,000 new diagnoses occurring annually, and occupational exposure contributing to nearly 9–15% of adult-onset asthma cases.Therefore, the increasing global burden of asthma is driving the growth of the mepolizumab industry. The growing adoption of biologic treatments is expected to drive the growth of the mepolizumab industry going forward.Biologic treatments are advanced therapeutic agents derived from living organisms or their components, designed to target specific molecular pathways involved in disease pathogenesis, particularly in immune-mediated and inflammatory conditions.A key factor driving the growing adoption of biologic treatments is their ability to deliver highly targeted mechanisms of action, which enables improved clinical outcomes with reduced off-target effects compared to conventional therapies, thereby increasing physician confidence and patient preference for precision-based interventions.Mepolizumab selectively inhibits interleukin-5, demonstrating the clinical value of biologic treatments in effectively managing eosinophilic conditions and reinforcing their adoption in respiratory care.For instance, in August 2023, according to the British Generic Manufacturers Association, a UK-based trade association, forecasts from the Office of Health Economics indicate that National Health Service biosimilar sales are expected to reach approximately $33 billion (£26 billion) over the period from 2023 to 2028.Therefore, the growing adoption of biologic treatments is driving the growth of the mepolizumab industry.

Key Players In The Global Mepolizumab Market

Major companies operating in the mepolizumab market are GlaxoSmithKline plc, Bio‑Thera Solutions Ltd.

Global Mepolizumab Market Trends and Insights

Major companies operating in the mepolizumab market are focusing on developing innovative products, such as eosinophil-targeting biologics to expand therapeutic indications and improve disease management outcomes. An eosinophil-targeting biologic is a monoclonal antibody therapy that inhibits interleukin-5 to reduce eosinophil-mediated inflammation. For instance, in January 2026, GlaxoSmithKline PLC, a UK-based biopharmaceutical company, announced China’s National Medical Products Administration (NMPA) approval of Nucala (mepolizumab). The therapy demonstrates statistically significant reductions in moderate to severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease when added to standard inhaled treatments. Its approval introduces a targeted biologic option in a large patient population, supporting improved clinical outcomes and reducing hospitalization burden.

Regional Insights

North America was the largest region in the mepolizumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mepolizumab Market?

The mepolizumab market consists of sales of products such as lyophilized powder for reconstitution into a subcutaneous injection, a prefilled syringe for subcutaneous administration, and a single-use autoinjector designed for subcutaneous delivery. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Mepolizumab Industry?

The mepolizumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mepolizumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Mepolizumab Market Report 2026?

The mepolizumab market research report is one of a series of new reports from The Business Research Company that provides mepolizumab market statistics, including mepolizumab industry global market size, regional shares, competitors with a mepolizumab market share, detailed mepolizumab market segments, market trends and opportunities, and any further data you may need to thrive in the mepolizumab industry. This mepolizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.